QuickView: In fair Verona, where we lay our scene…
Verona’s £44.7m gross raise removes funding uncertainty, allowing the company to focus on the clinical progress of its respiratory asset RPL554, a dual PDE3/PDE4 inhibitor. RPL554 is in development in chronic obstructive pulmonary disease (COPD) and cystic fibrosis. Verona now has the resources to run a Phase II programme, taking it through multiple potential value infection points in the next 18-24 months, and has committed to raising further funds via a future NASDAQ listing.Verona Pharam a clinical stage biopharmaceutical company focused on developing and commercialising therapeutics for the treatment of respiratory diseases with significant unmet medical needs. Co.'s product candidate, RPL554, is an inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4, that acts as both a bronchodilator and an anti-inflammatory agent in a single compound. Co. is developing RPL554 for the treatment of patients with chronic obstructive pulmonary disease, as well as for the treatment of cystic fibrosis, a fatal inherited disease. Co. may also explore, alone or with a collaborator, the development of RPL554 to treat asthma and other respiratory diseases.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.